FR16C0031I2 - S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih - Google Patents

S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih

Info

Publication number
FR16C0031I2
FR16C0031I2 FR16C0031C FR16C0031C FR16C0031I2 FR 16C0031 I2 FR16C0031 I2 FR 16C0031I2 FR 16C0031 C FR16C0031 C FR 16C0031C FR 16C0031 C FR16C0031 C FR 16C0031C FR 16C0031 I2 FR16C0031 I2 FR 16C0031I2
Authority
FR
France
Prior art keywords
mercaptoacetanilides
reverse transcriptase
transcriptase inhibitors
hiv reverse
triazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0031C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of FR16C0031I1 publication Critical patent/FR16C0031I1/fr
Application granted granted Critical
Publication of FR16C0031I2 publication Critical patent/FR16C0031I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
FR16C0031C 2004-08-25 2016-07-29 S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih Active FR16C0031I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60421904P 2004-08-25 2004-08-25
US60422004P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
EP05790722A EP1789039B1 (en) 2004-08-25 2005-08-25 S-triazolyl alpha -mercaptoacetanildes as inhibitors of hiv reverse transcriptase

Publications (2)

Publication Number Publication Date
FR16C0031I1 FR16C0031I1 (enrdf_load_html_response) 2016-09-23
FR16C0031I2 true FR16C0031I2 (fr) 2017-03-31

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0031C Active FR16C0031I2 (fr) 2004-08-25 2016-07-29 S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih

Country Status (31)

Country Link
US (8) US7947721B2 (enrdf_load_html_response)
EP (5) EP2135608B8 (enrdf_load_html_response)
JP (2) JP4952943B2 (enrdf_load_html_response)
KR (1) KR101241716B1 (enrdf_load_html_response)
CN (2) CN101817793B (enrdf_load_html_response)
AT (2) ATE528001T1 (enrdf_load_html_response)
AU (2) AU2005280130C9 (enrdf_load_html_response)
BR (2) BRPI0514630B8 (enrdf_load_html_response)
CA (1) CA2578068C (enrdf_load_html_response)
CY (2) CY1112221T1 (enrdf_load_html_response)
DK (1) DK2135608T3 (enrdf_load_html_response)
EA (2) EA014737B1 (enrdf_load_html_response)
EC (1) ECSP077322A (enrdf_load_html_response)
ES (2) ES2374773T3 (enrdf_load_html_response)
FR (1) FR16C0031I2 (enrdf_load_html_response)
HR (1) HRP20130075T1 (enrdf_load_html_response)
HU (1) HUS1600034I1 (enrdf_load_html_response)
IL (3) IL181523A (enrdf_load_html_response)
IN (1) IN2014CN03762A (enrdf_load_html_response)
LT (1) LTC2135608I2 (enrdf_load_html_response)
LU (1) LU93169I2 (enrdf_load_html_response)
ME (1) ME01512B (enrdf_load_html_response)
MX (1) MX2007002236A (enrdf_load_html_response)
NL (1) NL300825I2 (enrdf_load_html_response)
NZ (2) NZ553534A (enrdf_load_html_response)
PL (1) PL2135608T3 (enrdf_load_html_response)
PT (1) PT2135608E (enrdf_load_html_response)
RS (1) RS52632B (enrdf_load_html_response)
SG (2) SG185992A1 (enrdf_load_html_response)
SI (1) SI2135608T1 (enrdf_load_html_response)
WO (1) WO2006026356A2 (enrdf_load_html_response)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52632B (en) * 2004-08-25 2013-06-28 Ardea Biosciences Inc. S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
KR101542629B1 (ko) 2007-05-30 2015-08-06 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
BRPI0918586A2 (pt) 2008-09-04 2015-12-01 Ardea Biosciences Inc compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2349258A1 (en) * 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
EA020183B1 (ru) 2010-01-08 2014-09-30 Ардеа Биосайнсиз, Инк. Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3-илтио)ацетата натрия и их применение
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
JP5964821B2 (ja) 2010-06-15 2016-08-03 アルデア バイオサイエンシーズ インク． 痛風と高尿酸血症の処置
CA2802692C (en) 2010-06-16 2016-01-05 Ardea Biosciences, Inc. Phenylthioacetate compounds useful as uricosuric agents
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
WO2012092395A2 (en) 2010-12-30 2012-07-05 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
HUE040625T2 (hu) 2011-11-03 2019-03-28 Ardea Biosciences Inc 3,4-Diszubsztituált piridinvegyület, alkalmazási eljárása és ezt tartalmazó készítmények
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
WO2014198241A1 (en) * 2013-06-14 2014-12-18 Sunshine Lake Pharma Co., Ltd. Thio-1,2,4-triazole derivatives and method for preparing the same
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
AU2014351486C1 (en) * 2013-11-22 2019-06-06 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
US10633351B2 (en) 2016-06-17 2020-04-28 Medshine Discovery Inc. Halogenated compound and axially chiral isomer thereof
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (zh) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 雷西纳得的晶型xv及其制备方法
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
JP7728864B2 (ja) 2021-05-28 2025-08-25 住友化学株式会社 シクロアルキルブロミドの製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2006A (en) * 1841-03-16 Clamp for crimping leather
US226186A (en) 1880-04-06 Car-coupling
JPS5641637B2 (enrdf_load_html_response) 1973-11-26 1981-09-29
US6832996B2 (en) 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
EP0910565A1 (en) 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
DE69943247D1 (de) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
WO2000037471A1 (en) 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
DE69939749D1 (de) * 1998-12-25 2008-11-27 Shionogi & Co Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften
US6593077B2 (en) 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6995283B2 (en) 2001-03-02 2006-02-07 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7229987B2 (en) 2002-05-13 2007-06-12 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
AU2003295324B2 (en) 2002-08-23 2008-08-28 Ardea Biosciences,Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
WO2005028479A2 (en) 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
RS52632B (en) 2004-08-25 2013-06-28 Ardea Biosciences Inc. S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
EP2349258A1 (en) 2008-10-24 2011-08-03 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
LTC2135608I2 (lt) 2017-07-25
CA2578068C (en) 2011-08-09
SI2135608T1 (sl) 2012-03-30
AU2005280130B2 (en) 2009-09-10
ES2374773T3 (es) 2012-02-21
BRPI0514630A (pt) 2008-06-17
IL181523A0 (en) 2007-07-04
AU2009217458A8 (en) 2009-10-29
CN101083987B (zh) 2011-01-26
ATE528001T1 (de) 2011-10-15
JP5457472B2 (ja) 2014-04-02
EP2135608A1 (en) 2009-12-23
PL2135608T3 (pl) 2012-07-31
CN101083987A (zh) 2007-12-05
MX2007002236A (es) 2007-07-09
JP2008510828A (ja) 2008-04-10
FR16C0031I1 (enrdf_load_html_response) 2016-09-23
EA014737B1 (ru) 2011-02-28
JP4952943B2 (ja) 2012-06-13
SG185992A1 (en) 2012-12-28
AU2009217458B2 (en) 2009-11-19
ES2380604T3 (es) 2012-05-16
CY2016028I1 (el) 2016-12-14
US8003681B2 (en) 2011-08-23
HK1133582A1 (en) 2010-04-01
CN101817793A (zh) 2010-09-01
IL219131A0 (en) 2012-06-28
AU2009217458A1 (en) 2009-10-15
LU93169I2 (fr) 2016-10-10
EA015846B1 (ru) 2011-12-30
US7947721B2 (en) 2011-05-24
IL181523A (en) 2013-12-31
EP1789039B1 (en) 2012-01-11
EP2135608B8 (en) 2012-03-21
US20150094284A1 (en) 2015-04-02
DK2135608T3 (da) 2012-01-23
PT2135608E (pt) 2012-01-13
WO2006026356A2 (en) 2006-03-09
CY1112221T1 (el) 2015-12-09
US20100069645A1 (en) 2010-03-18
CY2016028I2 (el) 2016-12-14
EA200901186A1 (ru) 2010-04-30
BRPI0514630B1 (pt) 2020-09-15
EP2402011A1 (en) 2012-01-04
NL300825I2 (enrdf_load_html_response) 2017-01-24
US20080176850A1 (en) 2008-07-24
US20110313157A1 (en) 2011-12-22
AU2005280130A1 (en) 2006-03-09
CN101817793B (zh) 2014-01-08
LTPA2016024I1 (lt) 2016-09-12
BRPI0514630B8 (pt) 2021-05-25
CA2578068A1 (en) 2006-03-09
US20180002296A1 (en) 2018-01-04
EP2135608B1 (en) 2011-10-12
HUS1600034I1 (hu) 2016-09-28
ATE540677T1 (de) 2012-01-15
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
RS52632B (en) 2013-06-28
AU2005280130C9 (en) 2010-03-04
US8946273B2 (en) 2015-02-03
SG155246A1 (en) 2009-09-30
US20120283301A1 (en) 2012-11-08
US8252828B2 (en) 2012-08-28
EP1789039A2 (en) 2007-05-30
KR20070054694A (ko) 2007-05-29
US20100267724A2 (en) 2010-10-21
EP2433633A1 (en) 2012-03-28
NZ553534A (en) 2010-10-29
EA200700488A1 (ru) 2007-08-31
EP2402011B1 (en) 2012-11-14
US8481581B2 (en) 2013-07-09
EP1789039A4 (en) 2009-08-05
BRPI0520870B8 (pt) 2021-05-25
HRP20130075T1 (hr) 2013-02-28
IL201546A (en) 2013-10-31
IN2014CN03762A (enrdf_load_html_response) 2015-09-25
BRPI0520870B1 (pt) 2020-11-10
AU2005280130C1 (en) 2010-02-18
ME01512B (me) 2014-04-20
EP2609917A1 (en) 2013-07-03
US20110190491A1 (en) 2011-08-04
ECSP077322A (es) 2007-04-26
JP2012077088A (ja) 2012-04-19
US20100081827A1 (en) 2010-04-01
WO2006026356A3 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
FR16C0031I2 (fr) S-triazolyl alpha -mercaptoacetanilides en tant qu'inhibiteurs de la transcriptase inverse du vih
BR0309557A (pt) Inibidores da transcriptase reversa não nucleosìdeos
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
NO20071871L (no) Fosfoindoler som HIV-inhibitorer.
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
ATE373005T1 (de) Thienopyrrole als antivirale mittel
NO20073765L (no) Forbindelser for behandling av flaviviridae
DE60221508D1 (de) Aminosäurederivate als hiv-protease-inhibitoren
UY29170A1 (es) Adeninas sustituidas y usos de las mismas
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
ATE327725T1 (de) Kosmetikum zur reinigung und pflege der haut
RU2003100730A (ru) Способ пластики бифуркации сонной артерии
UA89200C2 (ru) S-ТРИАЗОЛИЛ-б-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
RU2004131162A (ru) Средство для лечения послеоперационных спаек в органах брюшной полости